Multicentre, parallel group, randomised, single-blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women

J. Y. Shim, Y. W. Park, B. H. Yoon, Y. K. Cho, J. H. Yang, Y. Lee, A. Kim

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Objective: To compare the efficacy and safety of atosiban with those of ritodrine in preterm labour. Design: Multicentre, single-blind, randomised, controlled trial. Setting: Obstetric units in six referral centres in Korea. Population: Women with singleton pregnancies with preterm labour, between 24 and 33 + 6 weeks of gestation. Methods: One hundred and twenty-eight women were randomised to receive intravenous atosiban (n = 63) or ritodrine (n = 65) and were stratified by gestational age (<28 weeks and ≥28 weeks). Atosiban or ritodrine was administered for up to 48 hours. Progression of labour was assessed by the frequency of contractions and cervical dilatation and effacement. Alternative tocolysis could be given as rescue therapy. Main outcome measure: Efficacy was assessed as the proportion of women in each group who did not deliver and did not need alternative tocolytic therapy at 48 hours and 7 days after therapy initiation. Safety was assessed as the numbers of maternal adverse events and neonatal morbidity. Results: Tocolytic efficacy after 7 days was significantly better in the atosiban group than in the ritodrine group (60.3 versus 34.9%), but not at 48 hours (68.3 versus 58.7%). Maternal adverse events related to therapy were reported less frequently in the atosiban group (7.9 vs 70.8%; P = 0.0001), resulting in fewer early drug terminations due to adverse events (0 versus 20.0%; P = 0.0001). This, however, was not accompanied by a concurrent improvement in perinatal outcomes. Conclusion: The efficacy and safety of atosiban in the treatment of preterm labour were superior to those of ritodrine.

Original languageEnglish
Pages (from-to)1228-1234
Number of pages7
JournalBJOG: An International Journal of Obstetrics and Gynaecology
Volume113
Issue number11
DOIs
StatePublished - 1 Nov 2006

Fingerprint

Ritodrine
Single-Blind Method
Premature Obstetric Labor
Safety
Tocolysis
Therapeutics
Mothers
Tocolytic Agents
First Labor Stage
Pregnancy
Korea
Complementary Therapies
Gestational Age
Obstetrics
atosiban
Referral and Consultation
Randomized Controlled Trials
Outcome Assessment (Health Care)
Morbidity
Pharmaceutical Preparations

Keywords

  • Atosiban
  • Preterm labour
  • Ritodrine

Cite this

@article{3bace979f5124826be22764dc5c9a3a2,
title = "Multicentre, parallel group, randomised, single-blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women",
abstract = "Objective: To compare the efficacy and safety of atosiban with those of ritodrine in preterm labour. Design: Multicentre, single-blind, randomised, controlled trial. Setting: Obstetric units in six referral centres in Korea. Population: Women with singleton pregnancies with preterm labour, between 24 and 33 + 6 weeks of gestation. Methods: One hundred and twenty-eight women were randomised to receive intravenous atosiban (n = 63) or ritodrine (n = 65) and were stratified by gestational age (<28 weeks and ≥28 weeks). Atosiban or ritodrine was administered for up to 48 hours. Progression of labour was assessed by the frequency of contractions and cervical dilatation and effacement. Alternative tocolysis could be given as rescue therapy. Main outcome measure: Efficacy was assessed as the proportion of women in each group who did not deliver and did not need alternative tocolytic therapy at 48 hours and 7 days after therapy initiation. Safety was assessed as the numbers of maternal adverse events and neonatal morbidity. Results: Tocolytic efficacy after 7 days was significantly better in the atosiban group than in the ritodrine group (60.3 versus 34.9{\%}), but not at 48 hours (68.3 versus 58.7{\%}). Maternal adverse events related to therapy were reported less frequently in the atosiban group (7.9 vs 70.8{\%}; P = 0.0001), resulting in fewer early drug terminations due to adverse events (0 versus 20.0{\%}; P = 0.0001). This, however, was not accompanied by a concurrent improvement in perinatal outcomes. Conclusion: The efficacy and safety of atosiban in the treatment of preterm labour were superior to those of ritodrine.",
keywords = "Atosiban, Preterm labour, Ritodrine",
author = "Shim, {J. Y.} and Park, {Y. W.} and Yoon, {B. H.} and Cho, {Y. K.} and Yang, {J. H.} and Y. Lee and A. Kim",
year = "2006",
month = "11",
day = "1",
doi = "10.1111/j.1471-0528.2006.01053.x",
language = "English",
volume = "113",
pages = "1228--1234",
journal = "BJOG: An International Journal of Obstetrics and Gynaecology",
issn = "1470-0328",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "11",

}

Multicentre, parallel group, randomised, single-blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women. / Shim, J. Y.; Park, Y. W.; Yoon, B. H.; Cho, Y. K.; Yang, J. H.; Lee, Y.; Kim, A.

In: BJOG: An International Journal of Obstetrics and Gynaecology, Vol. 113, No. 11, 01.11.2006, p. 1228-1234.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Multicentre, parallel group, randomised, single-blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women

AU - Shim, J. Y.

AU - Park, Y. W.

AU - Yoon, B. H.

AU - Cho, Y. K.

AU - Yang, J. H.

AU - Lee, Y.

AU - Kim, A.

PY - 2006/11/1

Y1 - 2006/11/1

N2 - Objective: To compare the efficacy and safety of atosiban with those of ritodrine in preterm labour. Design: Multicentre, single-blind, randomised, controlled trial. Setting: Obstetric units in six referral centres in Korea. Population: Women with singleton pregnancies with preterm labour, between 24 and 33 + 6 weeks of gestation. Methods: One hundred and twenty-eight women were randomised to receive intravenous atosiban (n = 63) or ritodrine (n = 65) and were stratified by gestational age (<28 weeks and ≥28 weeks). Atosiban or ritodrine was administered for up to 48 hours. Progression of labour was assessed by the frequency of contractions and cervical dilatation and effacement. Alternative tocolysis could be given as rescue therapy. Main outcome measure: Efficacy was assessed as the proportion of women in each group who did not deliver and did not need alternative tocolytic therapy at 48 hours and 7 days after therapy initiation. Safety was assessed as the numbers of maternal adverse events and neonatal morbidity. Results: Tocolytic efficacy after 7 days was significantly better in the atosiban group than in the ritodrine group (60.3 versus 34.9%), but not at 48 hours (68.3 versus 58.7%). Maternal adverse events related to therapy were reported less frequently in the atosiban group (7.9 vs 70.8%; P = 0.0001), resulting in fewer early drug terminations due to adverse events (0 versus 20.0%; P = 0.0001). This, however, was not accompanied by a concurrent improvement in perinatal outcomes. Conclusion: The efficacy and safety of atosiban in the treatment of preterm labour were superior to those of ritodrine.

AB - Objective: To compare the efficacy and safety of atosiban with those of ritodrine in preterm labour. Design: Multicentre, single-blind, randomised, controlled trial. Setting: Obstetric units in six referral centres in Korea. Population: Women with singleton pregnancies with preterm labour, between 24 and 33 + 6 weeks of gestation. Methods: One hundred and twenty-eight women were randomised to receive intravenous atosiban (n = 63) or ritodrine (n = 65) and were stratified by gestational age (<28 weeks and ≥28 weeks). Atosiban or ritodrine was administered for up to 48 hours. Progression of labour was assessed by the frequency of contractions and cervical dilatation and effacement. Alternative tocolysis could be given as rescue therapy. Main outcome measure: Efficacy was assessed as the proportion of women in each group who did not deliver and did not need alternative tocolytic therapy at 48 hours and 7 days after therapy initiation. Safety was assessed as the numbers of maternal adverse events and neonatal morbidity. Results: Tocolytic efficacy after 7 days was significantly better in the atosiban group than in the ritodrine group (60.3 versus 34.9%), but not at 48 hours (68.3 versus 58.7%). Maternal adverse events related to therapy were reported less frequently in the atosiban group (7.9 vs 70.8%; P = 0.0001), resulting in fewer early drug terminations due to adverse events (0 versus 20.0%; P = 0.0001). This, however, was not accompanied by a concurrent improvement in perinatal outcomes. Conclusion: The efficacy and safety of atosiban in the treatment of preterm labour were superior to those of ritodrine.

KW - Atosiban

KW - Preterm labour

KW - Ritodrine

UR - http://www.scopus.com/inward/record.url?scp=33750070936&partnerID=8YFLogxK

U2 - 10.1111/j.1471-0528.2006.01053.x

DO - 10.1111/j.1471-0528.2006.01053.x

M3 - Article

C2 - 16978233

AN - SCOPUS:33750070936

VL - 113

SP - 1228

EP - 1234

JO - BJOG: An International Journal of Obstetrics and Gynaecology

JF - BJOG: An International Journal of Obstetrics and Gynaecology

SN - 1470-0328

IS - 11

ER -